ClinicalTrials.gg
CompletedNCT02434497Updated Feb 27, 2018Results posted

A Study to Evaluate the Safety of Rosuvastatin in Children and Adolescents With Homozygous Familial Hypercholesterolemia

A Phase 3 interventional study of Rosuvastatin 20mg in Homozygous Familial Hypercholesterolemia (HoFH), sponsored by AstraZeneca. Completed at 6 sites in 6 countries. Open to participants aged 6 Years to 18 Years. Per ClinicalTrials.gov, last updated 2018-02-27.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
9
Allocation
Not applicable
Ages
6 Years to 18 Years
Sex
All
01

Study summary

The purpose of the study is to evaluate the safety of Rosuvastatin in Children and Adolescents with Homozygous Familial Hypercholesterolemia.

Read the detailed description

This is a long-term extension (LTE) to the randomized, double-blind, cross-over study of rosuvastatin 20 mg once daily (QD) versus placebo QD in children and adolescents (aged from 6 to \<18 years) with homozygous familial hypercholesterolemia (HoFH) (Study D3561C00004).

The study is designed to assess the long-term safety and tolerability of rosuvastatin 20 mg in pediatric patients with HoFH.

In this study all patients will receive rosuvastatin 20 mg QD. Investigators will also be permitted to titrate the dose of rosuvastatin from 20 to 40 mg per day if they feel it is warranted to more aggressively treat patients' elevated LDL-C levels. This up-titration will not be permitted in Asian patients. Pharmacokinetic data of the trough plasma exposure of rosuvastatin will also be assessed for the pediatric patients with HoFH taking a daily dose of rosuvastatin 40 mg.

The primary outcome measures to be assessed include 1) Adverse events, including:

  • The frequency and severity of adverse events,
  • Rate of discontinuations due to adverse events,
  • Abnormal serum and urine laboratory values, electrocardiograms (ECGs), physical examinations, and vital signs; and 2) Assessments of growth.
02

Conditions studied

  • Homozygous Familial Hypercholesterolemia (HoFH)

Keywords

  • LDL-C
  • HoFH
  • Hyperlipidemia
03

In context

Homozygous Familial Hypercholesterolemia

68 studies on the registry are indexed under Homozygous Familial Hypercholesterolemia; 13 are open to participants now.

This study's enrollment of 9 is below the median of 21 across 51 interventional studies indexed under Homozygous Familial Hypercholesterolemia.

Browse Homozygous Familial Hypercholesterolemia studies →

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Prior to any study related procedures being performed, provision of written from a parent/both parents or guardian and statement of assent from the child or adolescent (if required by Institutional Review Board [IRB] or Independent Ethics Committee [IEC] according to local regulations and guidelines). Study D3561C00004 participants who have had their 18th birthday (adults) will be required to provide written informed consent. Communication should take place between the Investigator, patient/guardian and child/adolescent to confirm understanding and required compliance with the requirements of the study.
  2. Male and female children and adolescents who were aged 6 to \<18 years at the onset of Study D3561C00004 (even if they had their 18th birthday during that study) with:

    • Documentation of genetic testing confirming 2 mutated alleles of the LDL receptor gene locus; and/or
    • Documented untreated LDL C >500 mg/dL (12.9 mmol/L) and TG \<400 mg/dL (4.5 mmol/L) and at least 1 of the following criteria:

      • Tendinous and/or cutaneous xanthoma prior to 10 years of age; or
      • Documentation of HeFH in both parents by:
    • genetic and/or
    • clinical criteria
  3. Negative pregnancy test (b human chorionic gonadotropin analysis) prior to baseline in females of child bearing potential:

    • Female patients of child bearing potential must adhere to a pregnancy prevention method (abstinence, chemical, or mechanical) during the study and 3 months following the last dose;
    • Male patients should refrain from fathering a child (including sperm donation) during the study and up to 3 months following the last dose; and
  4. Were taking study drug at the end of Study D3561C00004 and are willing to follow all study procedures including adherence to dietary guidelines, study visits, fasting blood draws, and compliance with study treatment regimens.

Exclusion criteria

Exclusion Criteria:

  1. History of statin inducted myopathy or serious reaction to other HMG CoA reductase inhibitors (statins), including rosuvastatin, at Visit 1 of Study D3561C00004.
  2. Fasting serum glucose of >9.99 mmol/L (180 mg/dL) or glycosylated >9% during Study D3561C00004 or patients with a history of diabetic ketoacidosis within the past year.
  3. Uncontrolled hypothyroidism defined as thyroid stimulating hormone >1.5 times the (ULN) at any time during Study D3561C00004.
  4. Evidence of active liver disease or hepatic dysfunction (except a confirmed diagnosis of Gilbert's disease) as defined as non-transient elevations of or AST elevations ≥3 times the ULN or non-transient total ≥2 times the ULN during the Study D3561C00004.
  5. Definite or suspected personal history or family history of adverse drug reactions (ADRs), or hypersensitivity to drugs with a similar chemical structure to rosuvastatin as well as other statins.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    Single Arm

    One treatment period for all patients (\<1 year and 10 months), with the possibility to up-titrate dose to 40 mg of rosuvastatin for non-Asian patients.

    Drug: Rosuvastatin 20mg

Interventions

  • Active drug 1 or 2 tablets will be taken taken orally, QD, either in the morning or in the evening

06

What researchers measure

Primary outcomes

  1. The Number of Participants Who Experianced Adverse Events and Serious Adverse Events

    Time frame: 96 weeks

  2. Safety and Tolerability in Terms of Number of Participants Who Had Adverse Events, Discontinuations Due to Adverse Events

    Time frame: 96 weeks

  3. Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Basophils/Leukocytes (%) >Upper Limite of Normal (ULN)

    Time frame: 96 weeks

  4. Safety and Tolerability in Terms of Growth, Height

    Time frame: 96 weeks

  5. Safety and Tolerability in Terms of Abnormalitites in Sexual Maturation

    Time frame: 96 weeks

  6. Safety and Tolerability in Terms of Growth, Height SD-score (or Z-score)

    Height z-score is a dimensionless quantity derived by subtracting the population mean from the individual raw score, and then deviding the difference by the pouulation SD of the reference population. This indicates how many SDs and observation is above or below the general population mean.

    Time frame: 96 weeks

  7. Safety and Tolerability in Terms of Growth, Weight

    Time frame: 96 weeks

  8. Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Alanine Aminotransferase (U/L) >ULN

    Time frame: 96 weeks

  9. Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Albumin (g/dL) >ULN

    Time frame: 96 weeks

  10. Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Aspartate Aminotransferase (U/L) >ULN

    Time frame: 96 weeks

  11. Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Bicarbonate (Mol/L) <LLN

    Time frame: 96 weeks

  12. Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Bicarbonate (Mol/L) >ULN

    Time frame: 96 weeks

  13. Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Ery. Mean Corpuscular HGB Concentration (g/dL) <LLN

    Time frame: 96 weeks

  14. Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Ery. Mean Corpuscular HGB (pg) <LLN

    Time frame: 96 weeks

  15. Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Ery. Mean Corpuscular Volume (fL) <LLN

    Time frame: 96 weeks

  16. Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Ery. Mean Corpuscular Volume (fL) >ULN

    Time frame: 96 weeks

  17. Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Erythrocytes (10^12/L) <LLN

    Time frame: 96 weeks

  18. Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Erythrocytes (10^12/L) >ULN

    Time frame: 96 weeks

  19. Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Hematocrit (%) <LLN

    Time frame: 96 weeks

  20. Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Hemoglobin (g/dL) <LLN

    Time frame: 96 weeks

  21. Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Leukocytes >ULN

    Time frame: 96 weeks

  22. Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Lymphocytes/Leukocytes (%) <LLN

    Time frame: 96 weeks

  23. Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Lymphocytes/Leukocytes (%) >ULN

    Time frame: 96 weeks

  24. Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Monocytes/Leukocytes (%) >ULN

    Time frame: 96 weeks

  25. Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Platelets (10^9/L) >ULN

    Time frame: 96 weeks

  26. Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Blood Urea Nitrogen (mg/dL) <LLN

    Time frame: 96 weeks

  27. Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Chloride (mmol/L) >ULN

    Time frame: 96 weeks

  28. Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Creatine Kinase (U/L) >ULN

    Time frame: 96 weeks

  29. Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Glucose (mg/dL) >ULN

    Time frame: 96 weeks

  30. Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Lactate Dehydrogenase (U/L) <LLN

    Time frame: 96 weeks

  31. Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Phosphate (mg/dL) >ULN

    Time frame: 96 weeks

  32. Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Protein (g/dL) >ULN

    Time frame: 96 weeks

  33. Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Sodium (mmol/L) <LLN

    Time frame: 96 weeks

  34. Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Urate (mg/dL) >ULN

    Time frame: 96 weeks

  35. Safety and Tolerability in Terms of Abnormal Urine Laboratory Values, Urine Ketones

    Time frame: 96 weeks

  36. Safety and Tolerability in Terms of Abnormal Urine Laboratory Values, Urine Occult Blood

    Time frame: 96 weeks

  37. Safety and Tolerability in Terms of Abnormal Urine Laboratory Values, Urine Protein

    Time frame: 96 weeks

  38. Safety and Tolerability in Terms of Abnormal ECG, Abnormalities

    Time frame: 96 weeks

  39. Safety and Tolerability in Terms of Abnormal Physical Exams, Cardiovascular

    Time frame: 96 weeks

  40. Safety and Tolerability in Terms of Abnormal Physical Exams, General Appearance

    Time frame: 96 weeks

  41. Safety and Tolerability in Terms of Abnormal Physical Exams, Head and Neck

    Time frame: 96 weeks

  42. Safety and Tolerability in Terms of Abnormal Physical Exams, Musculoskeletal/Extremities

    Time frame: 96 weeks

  43. Safety and Tolerability in Terms of Abnormal Physical Exams, Skin

    Time frame: 96 weeks

  44. Safety and Tolerability in Terms of Abnormal Vital Signs

    Time frame: 96 weeks

Secondary outcomes

  1. Percent Change in LDL-C From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis

    Time frame: Up to 22 months

  2. Percent Change in HDL-C From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis

    Time frame: Up to 22 months

  3. Percent Change in Total Cholesterol (TC) From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis

    Time frame: Up to 22 months

  4. Percent Change in Triglycerides (TG) From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis

    Time frame: Up to 22 months

  5. Percent Change in Non-HDL-C From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis

    Time frame: Up to 22 months

  6. Percent Change in LDL-C/HDL-C From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis

    Time frame: Up to 22 months

  7. Percent Change in TC/HDL-C From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis

    Time frame: Up to 22 months

  8. Percent Change in Non-HDL-C/HDL-C From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis

    Time frame: Up to 22 months

  9. Percent Change in ApoB From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis

    Time frame: Up to 22 months

  10. Percent Change in ApoA-1 From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis

    Time frame: Up to 22 months

  11. Percent Change in ApoB/ApoA-1 From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis

    Time frame: Up to 22 months

  12. Pharmacokinetic Profile in Terms of Trough Concentrations in Pediatric HoFH Taking a Daily Dose of Rosuvastatin 40mg

    Time frame: Up to 22 months

07

Results

Posted Feb 27, 2018

Participant flow

The nine (9) patients recruited were all participants in the D3561C00004 HYDRA study (NCT02226198) four came from Sequence A and five from Sequence B

Participant flow — Overall Study
MilestoneOverall
Started9
Completed4
Not completed5

Outcome measures

PrimaryThe Number of Participants Who Experianced Adverse Events and Serious Adverse Events
Time frame:
96 weeks
Reported as:
Number · participants
The Number of Participants Who Experianced Adverse Events and Serious Adverse Events
participantsFull Analysis Set
The Number of Participants Who Experianced Adverse Events and Serious Adverse Events5
PrimarySafety and Tolerability in Terms of Number of Participants Who Had Adverse Events, Discontinuations Due to Adverse Events
Time frame:
96 weeks
Reported as:
Number · participants
Safety and Tolerability in Terms of Number of Participants Who Had Adverse Events, Discontinuations Due to Adverse Events
participantsFull Analysis Set
Safety and Tolerability in Terms of Number of Participants Who Had Adverse Events, Discontinuations Due to Adverse Events0
PrimarySafety and Tolerability in Terms of Abnormal Serum Laboratory Values, Basophils/Leukocytes (%) >Upper Limite of Normal (ULN)
Time frame:
96 weeks
Reported as:
Number · participants
Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Basophils/Leukocytes (%) >Upper Limite of Normal (ULN)
participantsSequence ASequence B
Baseline0 ± 23.570 ± 15.02
Week 60 ± 23.570 ± 15.32
Week 120 ± 23.900 ± 14.94
Week 180 ± 23.560 ± 14.83
Week 240 ± 24.020 ± 15.74
Week 360 ± 24.150 ± 15.61
Week 480 ± 24.250 ± 15.21
Week 601 ± 19.470 ± 16.37
Week 720 ± 20.220 ± 15.12
Week 840 ± 20.430 ± 17.27
Week 960 ± 25.460 ± 12.73
PrimarySafety and Tolerability in Terms of Growth, Height
Time frame:
96 weeks
Reported as:
Mean · cm
Safety and Tolerability in Terms of Growth, Height
cmSequence ASequence B
Baseline142.5 ± 23.57136.8 ± 15.02
Week 6143.5 ± 23.57136.8 ± 15.32
Week 12144.0 ± 23.90137.6 ± 14.94
Week 18145.3 ± 23.56138.0 ± 14.83
Week 24145.8 ± 24.02139.2 ± 15.74
Week 36147.0 ± 24.15140.6 ± 15.61
Week 48148.8 ± 24.25142.2 ± 15.21
Week 60158.0 ± 19.47144.0 ± 16.37
Week 72159.0 ± 20.22145.0 ± 15.12
Week 84159.7 ± 20.43148.3 ± 17.27
Week 96165.0 ± 25.46138.0 ± 12.73
PrimarySafety and Tolerability in Terms of Abnormalitites in Sexual Maturation
Time frame:
96 weeks
Reported as:
Number · participants
Safety and Tolerability in Terms of Abnormalitites in Sexual Maturation
participantsFull Analysis Set
Safety and Tolerability in Terms of Abnormalitites in Sexual Maturation0
PrimarySafety and Tolerability in Terms of Growth, Height SD-score (or Z-score)

Height z-score is a dimensionless quantity derived by subtracting the population mean from the individual raw score, and then deviding the difference by the pouulation SD of the reference population. This indicates how many SDs and observation is above or below the general population mean.

Time frame:
96 weeks
Reported as:
Mean · standard deviations
Safety and Tolerability in Terms of Growth, Height SD-score (or Z-score)
standard deviationsSequence ASequence B
Baseline-0.43 ± 2.025-1.05 ± 1.787
Week 6-0.48 ± 1.911-1.05 ± 1.871
Week 12-0.41 ± 1.975-1.19 ± 1.709
Week 18-0.43 ± 1.610-1.14 ± 1.705
Week 24-0.60 ± 1.730-0.96 ± 1.670
Week 36-0.43 ± 1.836-0.76 ± 1.727
Week 48-0.16 ± 1.781-0.72 ± 1.729
Week 600.05 ± 1.757-1.04 ± 1.604
Week 720.00 ± 1.635-0.87 ± 1.604
Week 840.08 ± 1.734-0.33 ± 1.627
Week 961.18 ± 0.436-0.51 ± 0.886
PrimarySafety and Tolerability in Terms of Growth, Weight
Time frame:
96 weeks
Reported as:
Mean · kg
Safety and Tolerability in Terms of Growth, Weight
kgSequence ASequence B
Baseline36.25 ± 14.71937.42 ± 16.089
Week 637.20 ± 16.23038.02 ± 16.700
Week 1237.93 ± 17.11038.16 ± 17.501
Week 1838.85 ± 17.63338.40 ± 16.688
Week 2439.15 ± 17.52139.00 ± 16.704
Week 3639.98 ± 18.29339.88 ± 15.015
Week 4841.00 ± 17.57941.16 ± 16.045
Week 6048.47 ± 16.93341.80 ± 15.656
Week 7248.43 ± 16.39342.10 ± 17.047
Week 8450.17 ± 16.73745.28 ± 19.143
Week 9657.35 ± 16.47633.55 ± 2.192
PrimarySafety and Tolerability in Terms of Abnormal Serum Laboratory Values, Alanine Aminotransferase (U/L) >ULN
Time frame:
96 weeks
Reported as:
Number · participants
Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Alanine Aminotransferase (U/L) >ULN
participantsSequence ASequence B
Baseline0 ± 23.570 ± 15.02
Week 60 ± 23.570 ± 15.32
Week 120 ± 23.901 ± 14.94
Week 180 ± 23.561 ± 14.83
Week 240 ± 24.020 ± 15.74
Week 360 ± 24.151 ± 15.61
Week 480 ± 24.251 ± 15.21
Week 600 ± 19.471 ± 16.37
Week 720 ± 20.221 ± 15.12
Week 840 ± 20.430 ± 17.27
Week 960 ± 25.460 ± 12.73
PrimarySafety and Tolerability in Terms of Abnormal Serum Laboratory Values, Albumin (g/dL) >ULN
Time frame:
96 weeks
Reported as:
Number · participants
Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Albumin (g/dL) >ULN
participantsSequence ASequence B
Baseline0 ± 23.571 ± 15.02
Week 60 ± 23.570 ± 15.32
Week 120 ± 23.900 ± 14.94
Week 180 ± 23.561 ± 14.83
Week 240 ± 24.020 ± 15.74
Week 360 ± 24.150 ± 15.61
Week 480 ± 24.250 ± 15.21
Week 600 ± 19.470 ± 16.37
Week 720 ± 20.220 ± 15.12
Week 840 ± 20.430 ± 17.27
Week 960 ± 25.460 ± 12.73
PrimarySafety and Tolerability in Terms of Abnormal Serum Laboratory Values, Aspartate Aminotransferase (U/L) >ULN
Time frame:
96 weeks
Reported as:
Number · participants
Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Aspartate Aminotransferase (U/L) >ULN
participantsSequence ASequence B
Baseline0 ± 23.570 ± 15.02
Week 60 ± 23.570 ± 15.32
Week 120 ± 23.900 ± 14.94
Week 180 ± 23.560 ± 14.83
Week 240 ± 24.020 ± 15.74
Week 360 ± 24.150 ± 15.61
Week 480 ± 24.250 ± 15.21
Week 600 ± 19.471 ± 16.37
Week 720 ± 20.220 ± 15.12
Week 840 ± 20.430 ± 17.27
Week 960 ± 25.460 ± 12.73
PrimarySafety and Tolerability in Terms of Abnormal Serum Laboratory Values, Bicarbonate (Mol/L) <LLN
Time frame:
96 weeks
Reported as:
Number · participants
Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Bicarbonate (Mol/L) <LLN
participantsSequence ASequence B
Baseline0 ± 23.570 ± 15.02
Week 60 ± 23.571 ± 15.32
Week 121 ± 23.901 ± 14.94
Week 180 ± 23.561 ± 14.83
Week 241 ± 24.021 ± 15.74
Week 361 ± 24.152 ± 15.61
Week 481 ± 24.251 ± 15.21
Week 601 ± 19.473 ± 16.37
Week 722 ± 20.221 ± 15.12
Week 841 ± 20.431 ± 17.27
Week 960 ± 25.461 ± 12.73
PrimarySafety and Tolerability in Terms of Abnormal Serum Laboratory Values, Bicarbonate (Mol/L) >ULN
Time frame:
96 weeks
Reported as:
Number · participants
Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Bicarbonate (Mol/L) >ULN
participantsSequence ASequence B
Baseline0 ± 23.570 ± 15.02
Week 60 ± 23.570 ± 15.32
Week 120 ± 23.900 ± 14.94
Week 180 ± 23.560 ± 14.83
Week 240 ± 24.020 ± 15.74
Week 360 ± 24.150 ± 15.61
Week 480 ± 24.250 ± 15.21
Week 600 ± 19.470 ± 16.37
Week 720 ± 20.221 ± 15.12
Week 840 ± 20.430 ± 17.27
Week 960 ± 25.460 ± 12.73
PrimarySafety and Tolerability in Terms of Abnormal Serum Laboratory Values, Ery. Mean Corpuscular HGB Concentration (g/dL) <LLN
Time frame:
96 weeks
Reported as:
Number · participants
Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Ery. Mean Corpuscular HGB Concentration (g/dL) <LLN
participantsSequence ASequence B
Baseline2 ± 23.573 ± 15.02
Week 60 ± 23.572 ± 15.32
Week 122 ± 23.902 ± 14.94
Week 181 ± 23.562 ± 14.83
Week 242 ± 24.023 ± 15.74
Week 361 ± 24.153 ± 15.61
Week 481 ± 24.254 ± 15.21
Week 601 ± 19.474 ± 16.37
Week 722 ± 20.223 ± 15.12
Week 842 ± 20.433 ± 17.27
Week 960 ± 25.461 ± 12.73
PrimarySafety and Tolerability in Terms of Abnormal Serum Laboratory Values, Ery. Mean Corpuscular HGB (pg) <LLN
Time frame:
96 weeks
Reported as:
Number · participants
Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Ery. Mean Corpuscular HGB (pg) <LLN
participantsSequence ASequence B
Baseline1 ± 23.573 ± 15.02
Week 61 ± 23.572 ± 15.32
Week 121 ± 23.902 ± 14.94
Week 181 ± 23.562 ± 14.83
Week 241 ± 24.022 ± 15.74
Week 361 ± 24.152 ± 15.61
Week 481 ± 24.253 ± 15.21
Week 600 ± 19.473 ± 16.37
Week 720 ± 20.223 ± 15.12
Week 840 ± 20.433 ± 17.27
Week 962 ± 25.461 ± 12.73
PrimarySafety and Tolerability in Terms of Abnormal Serum Laboratory Values, Ery. Mean Corpuscular Volume (fL) <LLN
Time frame:
96 weeks
Reported as:
Number · participants
Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Ery. Mean Corpuscular Volume (fL) <LLN
participantsSequence ASequence B
Baseline1 ± 23.572 ± 15.02
Week 61 ± 23.572 ± 15.32
Week 121 ± 23.902 ± 14.94
Week 181 ± 23.562 ± 14.83
Week 241 ± 24.022 ± 15.74
Week 361 ± 24.152 ± 15.61
Week 481 ± 24.252 ± 15.21
Week 600 ± 19.472 ± 16.37
Week 720 ± 20.223 ± 15.12
Week 840 ± 20.433 ± 17.27
Week 962 ± 25.461 ± 12.73
PrimarySafety and Tolerability in Terms of Abnormal Serum Laboratory Values, Ery. Mean Corpuscular Volume (fL) >ULN
Time frame:
96 weeks
Reported as:
Number · participants
Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Ery. Mean Corpuscular Volume (fL) >ULN
participantsSequence ASequence B
Baseline0 ± 23.570 ± 15.02
Week 60 ± 23.570 ± 15.32
Week 120 ± 23.900 ± 14.94
Week 180 ± 23.560 ± 14.83
Week 240 ± 24.020 ± 15.74
Week 360 ± 24.150 ± 15.61
Week 480 ± 24.250 ± 15.21
Week 600 ± 19.470 ± 16.37
Week 720 ± 20.220 ± 15.12
Week 841 ± 20.430 ± 17.27
Week 960 ± 25.460 ± 12.73
PrimarySafety and Tolerability in Terms of Abnormal Serum Laboratory Values, Erythrocytes (10^12/L) <LLN
Time frame:
96 weeks
Reported as:
Number · participants
Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Erythrocytes (10^12/L) <LLN
participantsSequence ASequence B
Baseline1 ± 23.570 ± 15.02
Week 60 ± 23.570 ± 15.32
Week 120 ± 23.901 ± 14.94
Week 180 ± 23.561 ± 14.83
Week 240 ± 24.020 ± 15.74
Week 360 ± 24.151 ± 15.61
Week 480 ± 24.250 ± 15.21
Week 600 ± 19.470 ± 16.37
Week 720 ± 20.221 ± 15.12
Week 840 ± 20.430 ± 17.27
Week 960 ± 25.460 ± 12.73
PrimarySafety and Tolerability in Terms of Abnormal Serum Laboratory Values, Erythrocytes (10^12/L) >ULN
Time frame:
96 weeks
Reported as:
Number · participants
Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Erythrocytes (10^12/L) >ULN
participantsSequence ASequence B
Baseline0 ± 23.571 ± 15.02
Week 60 ± 23.570 ± 15.32
Week 120 ± 23.901 ± 14.94
Week 180 ± 23.560 ± 14.83
Week 241 ± 24.022 ± 15.74
Week 360 ± 24.152 ± 15.61
Week 480 ± 24.251 ± 15.21
Week 600 ± 19.471 ± 16.37
Week 720 ± 20.222 ± 15.12
Week 840 ± 20.431 ± 17.27
Week 960 ± 25.461 ± 12.73
PrimarySafety and Tolerability in Terms of Abnormal Serum Laboratory Values, Hematocrit (%) <LLN
Time frame:
96 weeks
Reported as:
Number · participants
Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Hematocrit (%) <LLN
participantsSequence ASequence B
Baseline2 ± 23.572 ± 15.02
Week 62 ± 23.573 ± 15.32
Week 121 ± 23.902 ± 14.94
Week 181 ± 23.563 ± 14.83
Week 240 ± 24.021 ± 15.74
Week 361 ± 24.151 ± 15.61
Week 480 ± 24.252 ± 15.21
Week 600 ± 19.472 ± 16.37
Week 720 ± 20.221 ± 15.12
Week 840 ± 20.431 ± 17.27
Week 960 ± 25.460 ± 12.73
PrimarySafety and Tolerability in Terms of Abnormal Serum Laboratory Values, Hemoglobin (g/dL) <LLN
Time frame:
96 weeks
Reported as:
Number · participants
Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Hemoglobin (g/dL) <LLN
participantsSequence ASequence B
Baseline2 ± 23.573 ± 15.02
Week 62 ± 23.573 ± 15.32
Week 121 ± 23.903 ± 14.94
Week 181 ± 23.563 ± 14.83
Week 240 ± 24.022 ± 15.74
Week 361 ± 24.153 ± 15.61
Week 481 ± 24.253 ± 15.21
Week 600 ± 19.473 ± 16.37
Week 720 ± 20.223 ± 15.12
Week 840 ± 20.433 ± 17.27
Week 960 ± 25.461 ± 12.73
PrimarySafety and Tolerability in Terms of Abnormal Serum Laboratory Values, Leukocytes >ULN
Time frame:
96 weeks
Reported as:
Number · participants
Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Leukocytes >ULN
participantsSequence ASequence B
Baseline0 ± 23.570 ± 15.02
Week 60 ± 23.570 ± 15.32
Week 120 ± 23.900 ± 14.94
Week 180 ± 23.560 ± 14.83
Week 240 ± 24.020 ± 15.74
Week 360 ± 24.150 ± 15.61
Week 480 ± 24.251 ± 15.21
Week 600 ± 19.470 ± 16.37
Week 720 ± 20.220 ± 15.12
Week 840 ± 20.430 ± 17.27
Week 960 ± 25.460 ± 12.73
PrimarySafety and Tolerability in Terms of Abnormal Serum Laboratory Values, Lymphocytes/Leukocytes (%) <LLN
Time frame:
96 weeks
Reported as:
Number · participants
Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Lymphocytes/Leukocytes (%) <LLN
participantsSequence ASequence B
Baseline0 ± 23.570 ± 15.02
Week 60 ± 23.570 ± 15.32
Week 120 ± 23.900 ± 14.94
Week 180 ± 23.560 ± 14.83
Week 240 ± 24.020 ± 15.74
Week 360 ± 24.150 ± 15.61
Week 480 ± 24.251 ± 15.21
Week 600 ± 19.470 ± 16.37
Week 720 ± 20.220 ± 15.12
Week 840 ± 20.430 ± 17.27
Week 960 ± 25.460 ± 12.73
PrimarySafety and Tolerability in Terms of Abnormal Serum Laboratory Values, Lymphocytes/Leukocytes (%) >ULN
Time frame:
96 weeks
Reported as:
Number · participants
Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Lymphocytes/Leukocytes (%) >ULN
participantsSequence ASequence B
Baseline0 ± 23.571 ± 15.02
Week 60 ± 23.571 ± 15.32
Week 120 ± 23.901 ± 14.94
Week 180 ± 23.561 ± 14.83
Week 240 ± 24.021 ± 15.74
Week 360 ± 24.151 ± 15.61
Week 480 ± 24.251 ± 15.21
Week 600 ± 19.471 ± 16.37
Week 720 ± 20.220 ± 15.12
Week 840 ± 20.430 ± 17.27
Week 960 ± 25.460 ± 12.73
PrimarySafety and Tolerability in Terms of Abnormal Serum Laboratory Values, Monocytes/Leukocytes (%) >ULN
Time frame:
96 weeks
Reported as:
Number · participants
Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Monocytes/Leukocytes (%) >ULN
participantsSequence ASequence B
Baseline0 ± 23.570 ± 15.02
Week 60 ± 23.570 ± 15.32
Week 120 ± 23.900 ± 14.94
Week 180 ± 23.560 ± 14.83
Week 240 ± 24.020 ± 15.74
Week 360 ± 24.151 ± 15.61
Week 480 ± 24.250 ± 15.21
Week 600 ± 19.470 ± 16.37
Week 720 ± 20.220 ± 15.12
Week 840 ± 20.430 ± 17.27
Week 960 ± 25.460 ± 12.73
PrimarySafety and Tolerability in Terms of Abnormal Serum Laboratory Values, Platelets (10^9/L) >ULN
Time frame:
96 weeks
Reported as:
Number · participants
Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Platelets (10^9/L) >ULN
participantsSequence ASequence B
Baseline1 ± 23.570 ± 15.02
Week 60 ± 23.571 ± 15.32
Week 120 ± 23.900 ± 14.94
Week 180 ± 23.560 ± 14.83
Week 240 ± 24.021 ± 15.74
Week 360 ± 24.150 ± 15.61
Week 480 ± 24.250 ± 15.21
Week 600 ± 19.470 ± 16.37
Week 720 ± 20.221 ± 15.12
Week 840 ± 20.430 ± 17.27
Week 960 ± 25.460 ± 12.73
SecondaryPercent Change in LDL-C From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis
Time frame:
Up to 22 months
Reported as:
Geometric mean · % change from baseline LDL-C
Percent Change in LDL-C From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis
% change from baseline LDL-CFull Analysis Set
Visit 1-21.0 (-32.1 to -8.0)
Visit 2-18.6 (-28.4 to -7.4)
Visit 3-14.7 (-25.2 to -2.8)
Visit 4-12.1 (-23.8 to 1.4)
Visit 5-21.3 (-33.7 to -6.6)
Visit 6-20.5 (-33.6 to -4.8)
Visit 7-12.4 (-28.2 to 7.0)
SecondaryPercent Change in HDL-C From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis
Time frame:
Up to 22 months
Reported as:
Geometric mean · % change from baseline HDL-C
Percent Change in HDL-C From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis
% change from baseline HDL-CFull Analysis Set
Visit 112.3 (1.3 to 24.5)
Visit 219.0 (6.2 to 33.4)
Visit 35.2 (-8.4 to 20.8)
Visit 44.4 (-10.8 to 22.2)
Visit 54.4 (-12.7 to 24.9)
Visit 69.4 (-9.4 to 32.1)
Visit 73.8 (-13.1 to 23.9)
SecondaryPercent Change in Total Cholesterol (TC) From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis
Time frame:
Up to 22 months
Reported as:
Geometric mean · % change from baseline TC
Percent Change in Total Cholesterol (TC) From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis
% change from baseline TCFull Analysis Set
Visit 1-19.4 (-29.7 to -7.6)
Visit 2-16.8 (-25.7 to -6.8)
Visit 3-14.0 (-23.6 to -3.3)
Visit 4-11.8 (-22.3 to 0.1)
Visit 5-19.9 (-31.1 to -6.9)
Visit 6-18.3 (-30.2 to -4.3)
Visit 7-11.9 (-26.3 to 5.2)
SecondaryPercent Change in Triglycerides (TG) From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis
Time frame:
Up to 22 months
Reported as:
Geometric mean · % change from baseline TG
Percent Change in Triglycerides (TG) From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis
% change from baseline TGFull Analysis Set
Visit 1-17.3 (-31.9 to 0.5)
Visit 2-17.4 (-34.2 to 3.8)
Visit 3-16.2 (-36.1 to 10.1)
Visit 4-22.0 (-42.8 to 6.5)
Visit 5-23.3 (-45.0 to 7.1)
Visit 6-21.7 (-43.4 to 8.4)
Visit 7-28.5 (-47.0 to -3.6)
SecondaryPercent Change in Non-HDL-C From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis
Time frame:
Up to 22 months
Reported as:
Geometric mean · % change from baseline Non-HDL-C
Percent Change in Non-HDL-C From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis
% change from baseline Non-HDL-CFull Analysis Set
Visit 1-21.7 (-32.7 to -9.0)
Visit 2-19.2 (-28.8 to -8.3)
Visit 3-15.7 (-25.7 to -4.3)
Visit 4-13.3 (-24.3 to -0.7)
Visit 5-22.1 (-33.8 to -8.4)
Visit 6-21.0 (-33.2 to -6.5)
Visit 7-13.2 (-28.1 to 4.8)
SecondaryPercent Change in LDL-C/HDL-C From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis
Time frame:
Up to 22 months
Reported as:
Geometric mean · % change from baseline LDL-C/HDL-C
Percent Change in LDL-C/HDL-C From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis
% change from baseline LDL-C/HDL-CFull Analysis Set
Visit 1-39.4 (-51.6 to -24.1)
Visit 2-41.2 (-52.8 to -26.9)
Visit 3-36.1 (-48.8 to -20.2)
Visit 4-35.0 (-49.5 to -16.4)
Visit 5-48.6 (-61.3 to -31.7)
Visit 6-42.2 (-57.2 to -21.9)
Visit 7-27.8 (-47.4 to -0.9)
SecondaryPercent Change in TC/HDL-C From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis
Time frame:
Up to 22 months
Reported as:
Geometric mean · % change from baseline TC/HDL-C
Percent Change in TC/HDL-C From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis
% change from baseline TC/HDL-CFull Analysis Set
Visit 1-30.6 (-38.3 to -21.9)
Visit 2-29.4 (-38.5 to -18.9)
Visit 3-20.5 (-32.0 to -7.0)
Visit 4-16.6 (-30.7 to 0.4)
Visit 5-24.1 (-38.6 to -6.2)
Visit 6-29.2 (-43.2 to -11.7)
Visit 7-15.6 (-33.7 to 7.5)
SecondaryPercent Change in Non-HDL-C/HDL-C From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis
Time frame:
Up to 22 months
Reported as:
Geometric mean · % change from baseline Non-HDL-C/HDL-C
Percent Change in Non-HDL-C/HDL-C From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis
% change from baseline Non-HDL-C/HDL-CFull Analysis Set
Visit 1-32.9 (-41.2 to -23.3)
Visit 2-31.5 (-41.2 to -20.3)
Visit 3-22.3 (-34.3 to -8.1)
Visit 4-18.1 (-32.8 to -0.3)
Visit 5-26.3 (-41.3 to -7.4)
Visit 6-31.8 (-46.0 to -13.9)
Visit 7-17.6 (-36.2 to 6.5)
SecondaryPercent Change in ApoB From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis
Time frame:
Up to 22 months
Reported as:
Geometric mean · % change from baseline ApoB
Percent Change in ApoB From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis
% change from baseline ApoBFull Analysis Set
Visit 1-20.5 (-29.8 to -9.9)
Visit 2-18.7 (-26.7 to -9.8)
Visit 3-15.2 (-23.9 to -5.6)
Visit 4-10.5 (-20.4 to 0.5)
Visit 5-17.2 (-27.9 to -4.9)
Visit 6-19.2 (-30.2 to -6.5)
Visit 7-9.5 (-23.5 to 7.2)
SecondaryPercent Change in ApoA-1 From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis
Time frame:
Up to 22 months
Reported as:
Geometric mean · % change from baseline ApoA-1
Percent Change in ApoA-1 From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis
% change from baseline ApoA-1Full Analysis Set
Visit 18.0 (0.0 to 16.6)
Visit 27.0 (-2.3 to 17.1)
Visit 35.3 (-4.9 to 16.7)
Visit 46.5 (-5.3 to 19.7)
Visit 51.0 (-11.5 to 15.3)
Visit 610.7 (-2.6 to 25.7)
Visit 71.6 (-12.9 to 18.4)
SecondaryPercent Change in ApoB/ApoA-1 From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis
Time frame:
Up to 22 months
Reported as:
Geometric mean · % change from baseline ApoB/ApoA-1
Percent Change in ApoB/ApoA-1 From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis
% change from baseline ApoB/ApoA-1Full Analysis Set
Visit 1-23.3 (-34.3 to -10.5)
Visit 2-22.1 (-32.7 to -9.8)
Visit 3-18.9 (-31.2 to -4.4)
Visit 4-15.7 (-30.2 to 1.7)
Visit 5-17.0 (-33.1 to 2.8)
Visit 6-26.0 (-41.1 to -7.0)
Visit 7-14.7 (-33.7 to 9.7)
SecondaryPharmacokinetic Profile in Terms of Trough Concentrations in Pediatric HoFH Taking a Daily Dose of Rosuvastatin 40mg
Time frame:
Up to 22 months
Reported as:
Number · ng/mL
Pharmacokinetic Profile in Terms of Trough Concentrations in Pediatric HoFH Taking a Daily Dose of Rosuvastatin 40mg
ng/mLFull Analysis Set
Day 2929.00
Day 3767.14
PrimarySafety and Tolerability in Terms of Abnormal Serum Laboratory Values, Blood Urea Nitrogen (mg/dL) <LLN
Time frame:
96 weeks
Reported as:
Number · participants
Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Blood Urea Nitrogen (mg/dL) <LLN
participantsSequence ASequence B
Baseline1 ± 23.570 ± 15.02
Week 61 ± 23.570 ± 15.32
Week 121 ± 23.900 ± 14.94
Week 181 ± 23.560 ± 14.83
Week 240 ± 24.020 ± 15.74
Week 360 ± 24.151 ± 15.61
Week 481 ± 24.250 ± 15.21
Week 600 ± 19.470 ± 16.37
Week 720 ± 20.220 ± 15.12
Week 840 ± 20.430 ± 17.27
Week 960 ± 25.460 ± 12.73
PrimarySafety and Tolerability in Terms of Abnormal Serum Laboratory Values, Chloride (mmol/L) >ULN
Time frame:
96 weeks
Reported as:
Number · participants
Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Chloride (mmol/L) >ULN
participantsSequence ASequence B
Baseline0 ± 23.571 ± 15.02
Week 60 ± 23.571 ± 15.32
Week 120 ± 23.900 ± 14.94
Week 180 ± 23.561 ± 14.83
Week 240 ± 24.020 ± 15.74
Week 360 ± 24.151 ± 15.61
Week 480 ± 24.250 ± 15.21
Week 600 ± 19.471 ± 16.37
Week 720 ± 20.221 ± 15.12
Week 840 ± 20.430 ± 17.27
Week 960 ± 25.460 ± 12.73
PrimarySafety and Tolerability in Terms of Abnormal Serum Laboratory Values, Creatine Kinase (U/L) >ULN
Time frame:
96 weeks
Reported as:
Number · participants
Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Creatine Kinase (U/L) >ULN
participantsSequence ASequence B
Baseline0 ± 23.570 ± 15.02
Week 61 ± 23.570 ± 15.32
Week 120 ± 23.900 ± 14.94
Week 180 ± 23.560 ± 14.83
Week 241 ± 24.020 ± 15.74
Week 361 ± 24.150 ± 15.61
Week 480 ± 24.250 ± 15.21
Week 601 ± 19.470 ± 16.37
Week 720 ± 20.220 ± 15.12
Week 840 ± 20.430 ± 17.27
Week 961 ± 25.460 ± 12.73
PrimarySafety and Tolerability in Terms of Abnormal Serum Laboratory Values, Glucose (mg/dL) >ULN
Time frame:
96 weeks
Reported as:
Number · participants
Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Glucose (mg/dL) >ULN
participantsSequence ASequence B
Baseline0 ± 23.570 ± 15.02
Week 60 ± 23.570 ± 15.32
Week 120 ± 23.900 ± 14.94
Week 180 ± 23.561 ± 14.83
Week 240 ± 24.020 ± 15.74
Week 360 ± 24.150 ± 15.61
Week 480 ± 24.250 ± 15.21
Week 600 ± 19.470 ± 16.37
Week 720 ± 20.220 ± 15.12
Week 840 ± 20.431 ± 17.27
Week 960 ± 25.460 ± 12.73
PrimarySafety and Tolerability in Terms of Abnormal Serum Laboratory Values, Lactate Dehydrogenase (U/L) <LLN
Time frame:
96 weeks
Reported as:
Number · participants
Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Lactate Dehydrogenase (U/L) <LLN
participantsSequence ASequence B
Baseline0 ± 23.570 ± 15.02
Week 60 ± 23.570 ± 15.32
Week 120 ± 23.900 ± 14.94
Week 180 ± 23.560 ± 14.83
Week 240 ± 24.020 ± 15.74
Week 360 ± 24.150 ± 15.61
Week 480 ± 24.250 ± 15.21
Week 600 ± 19.470 ± 16.37
Week 720 ± 20.221 ± 15.12
Week 840 ± 20.430 ± 17.27
Week 960 ± 25.460 ± 12.73
PrimarySafety and Tolerability in Terms of Abnormal Serum Laboratory Values, Phosphate (mg/dL) >ULN
Time frame:
96 weeks
Reported as:
Number · participants
Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Phosphate (mg/dL) >ULN
participantsSequence ASequence B
Baseline0 ± 23.570 ± 15.02
Week 60 ± 23.570 ± 15.32
Week 120 ± 23.900 ± 14.94
Week 180 ± 23.561 ± 14.83
Week 240 ± 24.020 ± 15.74
Week 360 ± 24.150 ± 15.61
Week 480 ± 24.250 ± 15.21
Week 600 ± 19.470 ± 16.37
Week 720 ± 20.221 ± 15.12
Week 840 ± 20.431 ± 17.27
Week 960 ± 25.460 ± 12.73
PrimarySafety and Tolerability in Terms of Abnormal Serum Laboratory Values, Protein (g/dL) >ULN
Time frame:
96 weeks
Reported as:
Number · participants
Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Protein (g/dL) >ULN
participantsSequence ASequence B
Baseline0 ± 23.570 ± 15.02
Week 60 ± 23.570 ± 15.32
Week 120 ± 23.901 ± 14.94
Week 180 ± 23.560 ± 14.83
Week 240 ± 24.021 ± 15.74
Week 361 ± 24.150 ± 15.61
Week 480 ± 24.250 ± 15.21
Week 600 ± 19.470 ± 16.37
Week 720 ± 20.220 ± 15.12
Week 840 ± 20.430 ± 17.27
Week 960 ± 25.460 ± 12.73
PrimarySafety and Tolerability in Terms of Abnormal Serum Laboratory Values, Sodium (mmol/L) <LLN
Time frame:
96 weeks
Reported as:
Number · participants
Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Sodium (mmol/L) <LLN
participantsSequence ASequence B
Baseline2 ± 23.570 ± 15.02
Week 61 ± 23.570 ± 15.32
Week 120 ± 23.900 ± 14.94
Week 183 ± 23.561 ± 14.83
Week 240 ± 24.021 ± 15.74
Week 360 ± 24.150 ± 15.61
Week 480 ± 24.251 ± 15.21
Week 600 ± 19.470 ± 16.37
Week 720 ± 20.221 ± 15.12
Week 840 ± 20.430 ± 17.27
Week 960 ± 25.460 ± 12.73
PrimarySafety and Tolerability in Terms of Abnormal Serum Laboratory Values, Urate (mg/dL) >ULN
Time frame:
96 weeks
Reported as:
Number · participants
Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Urate (mg/dL) >ULN
participantsSequence ASequence B
Baseline1 ± 23.570 ± 15.02
Week 61 ± 23.571 ± 15.32
Week 121 ± 23.900 ± 14.94
Week 181 ± 23.561 ± 14.83
Week 241 ± 24.021 ± 15.74
Week 361 ± 24.151 ± 15.61
Week 481 ± 24.251 ± 15.21
Week 601 ± 19.471 ± 16.37
Week 721 ± 20.221 ± 15.12
Week 841 ± 20.431 ± 17.27
Week 961 ± 25.460 ± 12.73
PrimarySafety and Tolerability in Terms of Abnormal Urine Laboratory Values, Urine Ketones
Time frame:
96 weeks
Reported as:
Number · participants
Safety and Tolerability in Terms of Abnormal Urine Laboratory Values, Urine Ketones
participantsSequence ASequence B
Baseline0 ± 23.570 ± 15.02
Week 60 ± 23.570 ± 15.32
Week 120 ± 23.900 ± 14.94
Week 180 ± 23.561 ± 14.83
Week 240 ± 24.020 ± 15.74
Week 360 ± 24.150 ± 15.61
Week 480 ± 24.251 ± 15.21
Week 600 ± 19.470 ± 16.37
Week 720 ± 20.220 ± 15.12
Week 840 ± 20.430 ± 17.27
Week 961 ± 25.460 ± 12.73
PrimarySafety and Tolerability in Terms of Abnormal Urine Laboratory Values, Urine Occult Blood
Time frame:
96 weeks
Reported as:
Number · participants
Safety and Tolerability in Terms of Abnormal Urine Laboratory Values, Urine Occult Blood
participantsSequence ASequence B
Baseline1 ± 23.571 ± 15.02
Week 62 ± 23.571 ± 15.32
Week 121 ± 23.902 ± 14.94
Week 181 ± 23.561 ± 14.83
Week 241 ± 24.021 ± 15.74
Week 361 ± 24.151 ± 15.61
Week 481 ± 24.251 ± 15.21
Week 601 ± 19.471 ± 16.37
Week 722 ± 20.221 ± 15.12
Week 841 ± 20.431 ± 17.27
Week 960 ± 25.460 ± 12.73
PrimarySafety and Tolerability in Terms of Abnormal Urine Laboratory Values, Urine Protein
Time frame:
96 weeks
Reported as:
Number · participants
Safety and Tolerability in Terms of Abnormal Urine Laboratory Values, Urine Protein
participantsSequence ASequence B
Baseline2 ± 23.571 ± 15.02
Week 61 ± 23.571 ± 15.32
Week 122 ± 23.901 ± 14.94
Week 181 ± 23.560 ± 14.83
Week 242 ± 24.021 ± 15.74
Week 362 ± 24.150 ± 15.61
Week 481 ± 24.251 ± 15.21
Week 603 ± 19.471 ± 16.37
Week 723 ± 20.221 ± 15.12
Week 842 ± 20.431 ± 17.27
Week 961 ± 25.460 ± 12.73
PrimarySafety and Tolerability in Terms of Abnormal ECG, Abnormalities
Time frame:
96 weeks
Reported as:
Number · participants
Safety and Tolerability in Terms of Abnormal ECG, Abnormalities
participantsSequence ASequence B
Baseline0 ± 23.570 ± 15.02
Week 240 ± 24.020 ± 15.74
Final Visit0 ± 25.460 ± 12.73
PrimarySafety and Tolerability in Terms of Abnormal Physical Exams, Cardiovascular
Time frame:
96 weeks
Reported as:
Number · participants
Safety and Tolerability in Terms of Abnormal Physical Exams, Cardiovascular
participantsSequence ASequence B
Baseline0 ± 23.570 ± 15.02
Week 60 ± 23.570 ± 15.32
Week 120 ± 23.900 ± 14.94
Week 180 ± 23.560 ± 14.83
Week 240 ± 24.020 ± 15.74
Week 360 ± 24.151 ± 15.61
Week 480 ± 24.251 ± 15.21
Week 600 ± 19.471 ± 16.37
Week 720 ± 20.221 ± 15.12
Week 840 ± 20.430 ± 17.27
Week 960 ± 25.460 ± 12.73
PrimarySafety and Tolerability in Terms of Abnormal Physical Exams, General Appearance
Time frame:
96 weeks
Reported as:
Number · participants
Safety and Tolerability in Terms of Abnormal Physical Exams, General Appearance
participantsSequence ASequence B
Baseline1 ± 23.572 ± 15.02
Week 61 ± 23.572 ± 15.32
Week 121 ± 23.902 ± 14.94
Week 181 ± 23.562 ± 14.83
Week 241 ± 24.022 ± 15.74
Week 361 ± 24.152 ± 15.61
Week 481 ± 24.252 ± 15.21
Week 601 ± 19.472 ± 16.37
Week 721 ± 20.222 ± 15.12
Week 841 ± 20.432 ± 17.27
Week 960 ± 25.460 ± 12.73
PrimarySafety and Tolerability in Terms of Abnormal Physical Exams, Head and Neck
Time frame:
96 weeks
Reported as:
Number · participants
Safety and Tolerability in Terms of Abnormal Physical Exams, Head and Neck
participantsSequence ASequence B
Baseline0 ± 23.571 ± 15.02
Week 60 ± 23.571 ± 15.32
Week 120 ± 23.901 ± 14.94
Week 180 ± 23.561 ± 14.83
Week 240 ± 24.021 ± 15.74
Week 360 ± 24.151 ± 15.61
Week 480 ± 24.251 ± 15.21
Week 600 ± 19.471 ± 16.37
Week 720 ± 20.221 ± 15.12
Week 840 ± 20.430 ± 17.27
Week 960 ± 25.460 ± 12.73
PrimarySafety and Tolerability in Terms of Abnormal Physical Exams, Musculoskeletal/Extremities
Time frame:
96 weeks
Reported as:
Number · participants
Safety and Tolerability in Terms of Abnormal Physical Exams, Musculoskeletal/Extremities
participantsSequence ASequence B
Baseline0 ± 23.570 ± 15.02
Week 60 ± 23.570 ± 15.32
Week 120 ± 23.900 ± 14.94
Week 180 ± 23.560 ± 14.83
Week 240 ± 24.020 ± 15.74
Week 360 ± 24.150 ± 15.61
Week 480 ± 24.251 ± 15.21
Week 600 ± 19.470 ± 16.37
Week 720 ± 20.220 ± 15.12
Week 840 ± 20.430 ± 17.27
Week 960 ± 25.460 ± 12.73
PrimarySafety and Tolerability in Terms of Abnormal Physical Exams, Skin
Time frame:
96 weeks
Reported as:
Number · participants
Safety and Tolerability in Terms of Abnormal Physical Exams, Skin
participantsSequence ASequence B
Baseline3 ± 23.572 ± 15.02
Week 63 ± 23.572 ± 15.32
Week 123 ± 23.902 ± 14.94
Week 183 ± 23.562 ± 14.83
Week 243 ± 24.022 ± 15.74
Week 363 ± 24.152 ± 15.61
Week 483 ± 24.252 ± 15.21
Week 602 ± 19.472 ± 16.37
Week 722 ± 20.222 ± 15.12
Week 842 ± 20.431 ± 17.27
Week 962 ± 25.461 ± 12.73
PrimarySafety and Tolerability in Terms of Abnormal Vital Signs
Time frame:
96 weeks
Reported as:
Number · participants
Safety and Tolerability in Terms of Abnormal Vital Signs
participantsSequence ASequence B
Baseline0 ± 23.570 ± 15.02
Week 60 ± 23.570 ± 15.32
Week 120 ± 23.900 ± 14.94
Week 180 ± 23.560 ± 14.83
Week 240 ± 24.020 ± 15.74
Week 360 ± 24.150 ± 15.61
Week 480 ± 24.250 ± 15.21
Week 600 ± 19.470 ± 16.37
Week 720 ± 20.220 ± 15.12
Week 840 ± 20.430 ± 17.27
Week 960 ± 25.460 ± 12.73

Adverse events

Collected over 72 weeks. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Overall—0/9 (0%)5/9 (55.6%)
Most frequent other events
Most frequent other events
EventOverall
NasopharyngitisInfections and infestations2/9
Otitis externaInfections and infestations1/9
Upper respiratory tract infectionInfections and infestations1/9
DysuriaRenal and urinary disorders1/9
ProteinuriaRenal and urinary disorders1/9
Chest discomfortGeneral disorders1/9
Ligament sprainInjury, poisoning and procedural complications1/9
Attention deficit/hyperactivity disorderPsychiatric disorders1/9
DysmenorrhoeaReproductive system and breast disorders1/9

Baseline characteristics

Age, Continuous
Age, Continuous(years)Overall
Mean10.6 ± 2.83
Sex: Female, Male
Sex: Female, Male(Participants)Overall
Female4
Male5
08

Study locations

6 sites
  • Research Site
    Brussels (Woluwé-St-Lambert), 1200, Belgium
  • Research Site
    Chicoutimi, Quebec G7H 7K9, Canada
  • Research Site
    Copenhagen, DK-2100, Denmark
  • Research Site
    Halfa, 31096, Israel
  • Research Site
    Kubang Kerian, 16150, Malaysia
  • Research Site
    Taipei City, 11217, Taiwan
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2015 to primary completion in Nov 2016, 17 months.

Results were first posted in Feb 2018, 1 year 3 months after primary completion.

Of 20 phase 3 interventional studies under Homozygous Familial Hypercholesterolemia, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 34. This study's 17 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2015
First posted
May 5, 2015
StartActual
Jun 6, 2015
Primary completionActual
Nov 17, 2016
CompletionActual
Nov 17, 2016
Results first posted
Feb 27, 2018
Last update
Feb 27, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02434497
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
May 5, 2015
Start date
Jun 6, 2015
Primary completion
Nov 17, 2016
Completion
Nov 17, 2016
Results posted
Feb 27, 2018
Last update
Feb 27, 2018

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rosuvastatin

Start the discussion